Park Yang Shin, Lee Chang Hee, Kim Ji Hoon, Kim Baek Hui, Kim Jeoung Hyun, Kim Kyeong Ah, Park Cheol Min
Department of Radiology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
Department of Radiology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
Magn Reson Imaging. 2014 Sep;32(7):886-90. doi: 10.1016/j.mri.2014.04.010. Epub 2014 Apr 24.
To determine whether gadolinium ethoxybenzyldiethylenetriaminepentaacetic acid (Gd-EOB-DTPA) administration affects hepatic fat quantification by magnetic resonance spectroscopy (MRS) using the fast breath-hold high-speed T2-corrected multiecho (HISTO) technique.
Seventy-six patients underwent Gd-EOB-DTPA-enhanced liver MR and 15sec breath-hold HISTO MRS (4 times), twice before and twice after Gd-EOB-DTPA administration. Two consecutive MRSs were performed immediately before the dynamic study. Post-contrast MRS was performed twice continuously, approximately 15min after contrast injection, prior to obtaining 20-min hepatobiliary phase images. We used paired t-test and intraclass correlation coefficient (ICC) to evaluate the variability of the mean fat fraction (FF) on pre-contrast MRS and post-contrast MRS and the effect of the contrast agent on the mean FF.
The mean FFs were not significantly different between pre-contrast MRS and post-contrast MRS (6.50%±6.54 versus 6.70%±6.61, P=0.15). The ICC of FF calculation between pre- and post-contrast MRS was 0.984. The ICCs for the FF magnitude between pre- and post-contrast MRS were 0.452, 0.771, and 0.995 for FF <5%, FF 5-10%, and FF ≥10%, respectively.
Gd-EOB-DTPA does not appear to influence hepatic fat quantification, especially for patients with hepatic steatosis.
通过使用快速屏气高速T2校正多回波（HISTO）技术的磁共振波谱（MRS），确定乙氧基苄基二乙三胺五乙酸钆（Gd-EOB-DTPA）给药是否会影响肝脏脂肪定量。
76例患者接受了Gd-EOB-DTPA增强肝脏磁共振成像及15秒屏气HISTO MRS（4次），在Gd-EOB-DTPA给药前两次，给药后两次。在动态研究前立即进行连续两次MRS。在注射造影剂后约15分钟，在获取20分钟肝胆期图像之前，连续两次进行造影剂后MRS。我们使用配对t检验和组内相关系数（ICC）来评估造影剂前MRS和造影剂后MRS上平均脂肪分数（FF）的变异性以及造影剂对平均FF的影响。
造影剂前MRS和造影剂后MRS的平均FF无显著差异（6.50%±6.54对6.70%±6.61，P=0.15）。造影剂前和造影剂后MRS之间FF计算的ICC为0.984。造影剂前和造影剂后MRS之间FF幅度的ICC，对于FF<5%、FF 5-10%和FF≥10%分别为0.452、0.771和0.995。
Gd-EOB-DTPA似乎不会影响肝脏脂肪定量，尤其是对于肝脂肪变性患者。
